ArticleJournal of applied clinical medical physics2019
Dosimetric study of the plan quality and dose to organs at risk on tangential breast treatments using the Halcyon linac.
Article in Journal of applied clinical medical physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Benchmarking halcyon ring delivery system for hypofractionated breast radiotherapy: Validation and clinical implementation of the fast-forward trial.Journal of applied clinical medical physics · 2023Trial
- An end-to-end quality assurance procedure for pelvic VMAT using optically stimulated luminescence dosimeters and an anthropomorphic phantom.Physical and engineering sciences in medicine · 2026Article
- Comparative analysis of VMAT plans on Halcyon and infinity for lung cancer radiotherapy.PloS one · 2025Article
- Article
- Intensity Modulated Therapy for Patients With Breast Cancer. Practical Guidelines and Tips for an Effective Treatment Planning Strategy.Advances in radiation oncology · 2024Article
- Comparison of sliding window and field-in-field techniques for tangential whole breast irradiation using the Halcyon and Synergy Agility systems.Radiation oncology (London, England) · 2021Article
- Fast generation of lung SBRT plans with a knowledge-based planning model on ring-mounted Halcyon Linac.Journal of applied clinical medical physics · 2021Article
- Comparison of treatment plans for hypofractionated high-dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms.Journal of applied clinical medical physics · 2021Article
- SBRT treatment of abdominal and pelvic oligometastatic lymph nodes using ring-mounted Halcyon Linac.Journal of applied clinical medical physics · 2021Article
- Effect of treatment planning system parameters on beam modulation complexity for treatment plans with single-layer multi-leaf collimator and dual-layer stacked multi-leaf collimator.The British journal of radiology · 2021Article
- Treatment planning comparison of volumetric modulated arc therapy with the trilogy and the Halcyon for bilateral breast cancer.Radiation oncology (London, England) · 2021Article
- Clinical validation of ring-mounted halcyon linac for lung SBRT: comparison to SBRT-dedicated C-arm linac treatments.Journal of applied clinical medical physics · 2021Article
- Prostate SBRT using O-Ring Halcyon Linac - Plan quality, delivery efficiency, and accuracy.Journal of applied clinical medical physics · 2021Article
- Comprehensive validation of halcyon 2.0 plans and the implementation of patient specific QA with multiple detector platforms.Journal of applied clinical medical physics · 2020Article
- Treatment planning comparison of volumetric modulated arc therapy employing a dual-layer stacked multi-leaf collimator and helical tomotherapy for cervix uteri.Radiation oncology (London, England) · 2020Article
- Initial Clinical Experience Treating Patients With Gynecologic Cancers on a 6MV Flattening Filter Free O-Ring Linear Accelerator.Advances in radiation oncologyArticle
- Two-Level Factorial Pre-TomoBreast Pilot Study of Tomotherapy and Conventional Radiotherapy in Breast Cancer: Post Hoc Utility of a Mean Absolute Dose Deviation Penalty Score.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the plan quality and doses to the heart, contralateral breast (CB), ipsilateral lung (IL), and contralateral lung (CL) in tangential breast treatments using the Halcyon linac with megavoltage setup fields.
methodsRadiotherapy treatment plans with tangential beams from 25 breast cancer patients previously treated on a C-arm linac were replanned for Halcyon. Thirteen corresponded to right-sided breasts and 12 to left-sided breasts, all with a dose prescription of 50 Gy in 25 fractions. Plans were created with the following setup imaging techniques: low-dose (LD) MVCBCT, high-quality (HQ) MVCBCT, LD-MV and HQ-MV pairs and the imaging dose was included in the plans. Plan quality metric values for the lumpectomy cavity, whole-breast and doses to the organs at risk (OARs) were measured and compared with those from the original plans.
resultsNo significant differences in plan quality were observed between the original and Halcyon plans. An increase in the mean dose (Mean) for all the organs was observed for the Halcyon plans. For right-sided plans, the accumulated Mean over the 25 fractions in the C-arm plans was 0.4 ± 0.3, 0.2 ± 0.2, 5.4 ± 1.3, and 0.1 ± 0.1 Gy for the heart, CB, IL, and CL, respectively, while values in the MVCBCT-LD Halcyon plans were 1.2 ± 0.2, 0.6 ± 0.1, 6.5 ± 1.4, and 0.4 ± 0.1 Gy, respectively. For left-sided treatments, Mean in the original plans was 0.9 ± 0.2, 0.1 ± 0.0, 4.2 ± 1.2, and 0.0 ± 0.0 Gy, while for the MVCBCT-LD Halcyon plans values were 1.9 ± 0.2, 0.6 ± 0.2, 5.1 ± 1.2, and 0.5 ± 0.2 Gy, respectively.
conclusionsPlan quality for breast treatments using Halcyon is similar to the quality for a 6 MV, C-arm plan. For treatments using megavoltage setup fields, the dose contribution to OARs from the imaging fields can be equal or higher than the dose from treatment fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.